Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 186

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma

Leonard, John P., Kolibaba, Kathryn S., Reeves, James A., Tulpule, Anil, Flinn, Ian W., Kolevska, Tatjana, Robles, Robert, Flowers, Christopher R., Collins, Robert, DiBella, Nicholas J., Papish, Steven W., Venugopal, Parameswaran, Horodner, Andrew, Tabatabai, Amir, Hajdenberg, Julio, Park, Jaehong, Neuwirth, Rachel, Mulligan, George, Suryanarayan, Kaveri, Esseltine, Dixie-Lee, de Vos, Sven·2017·Journal of Clinical Oncology

Abstract

Purpose: To evaluate the impact of the addition of bortezomib to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on outcomes in previously untreated patients with non–germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL). Patients and Methods: After real-time determination of non-GCB DLBCL using the Hans immunohistochemistry algorithm, 206 patients were randomly assigned (1:1; stratified by International Prognostic Index [IPI] score) to six 21-day cycles of standard R-CHOP alone or R-CHOP plus bortezomib 1.3 mg/m 2 intravenously on days 1 and 4 (VR-CHOP). The primary end point, progression-free survival (PFS), was evaluated in 183 patients with centrally confirmed non-GCB DLBCL who received one or more doses of study drug (91 R-CHOP, 92 VR-CHOP). Results: After a median follow-up of 34 months, with 25% (R-CHOP) and 18% (VR-CHOP) of patients having had PFS events, the hazard ratio (HR) for PFS was 0.73 (90% CI, 0.43 to 1.24) with VR-CHOP ( P = .611). Two-year PFS rates were 77.6% with R-CHOP and 82.0% with VR-CHOP; they were 65.1% versus 72.4% in patients with high-intermediate/high IPI (HR, 0.67; 90% CI, 0.34 to 1.29), and 90.0% versus 88.9% (HR, 0.85; 90% CI, 0.35 to 2.10) in patients with low/low-intermediate IPI. Overall response rate with R-CHOP and VR-CHOP was 98% and 96%, respectively. The overall survival HR was 0.75 (90% CI, 0.38 to 1.45); 2-year survival rates were 88.4% and 93.0%, respectively. In the safety population (100 R-CHOP and 101 VR-CHOP patients), grade ≥ 3 adverse events included neutropenia (53% v 49%), thrombocytopenia (13% v 29%), anemia (7% v 15%), leukopenia (26% v 25%), and neuropathy (1% v 5%). Conclusion: Outcomes for newly diagnosed, prospectively enrolled patients with non-GCB DLBCL were more favorable than expected with R-CHOP and were not significantly improved by adding bortezomib.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.73.2784

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 186

Metadata

Authors
Leonard, J. P., Kolibaba, K. S., Reeves, J. A., Tulpule, A., Flinn, I. W., Kolevska, T., Robles, R., Flowers, C. R., Collins, R., DiBella, N. J., Papish, S. W., Venugopal, P., Horodner, A., Tabatabai, A., Hajdenberg, J., Park, J., Neuwirth, R., Mulligan, G., Suryanarayan, K., Esseltine, D.-L., & de Vos, S.
Venue
Journal of Clinical Oncology
Published
2017-11-01
Volume
35
Issue
31
Pages
3538-3546
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2751075585
Cited by
186
References
1
FWCI
18.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2017.73.2784
The paper
Leonard, J. P., Kolibaba, K. S., Reeves, J. A., Tulpule, A., Flinn, I. W., Kolevska, T., Robles, R., Flowers, C. R., Collins, R., DiBella, N. J., Papish, S. W., Venugopal, P., Horodner, A., Tabatabai, A., Hajdenberg, J., Park, J., Neuwirth, R., Mulligan, G., Suryanarayan, K., . . . de Vos, S. (2017). Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.73.2784

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.